| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 397 (10285), 1637-1645, 2021 | 1502 | 2021 |
| Safety and immunogenicity of novel adenovirus type 26–and modified vaccinia ankara–vectored ebola vaccines: a randomized clinical trial ID Milligan, MM Gibani, R Sewell, EA Clutterbuck, D Campbell, E Plested, ... Jama 315 (15), 1610-1623, 2016 | 378 | 2016 |
| Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a … C Jin, MM Gibani, M Moore, HB Juel, E Jones, J Meiring, V Harris, ... The Lancet 390 (10111), 2472-2480, 2017 | 307 | 2017 |
| A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA K Ewer, T Rampling, N Venkatraman, G Bowyer, D Wright, T Lambe, ... New England Journal of Medicine 374 (17), 1635-1646, 2016 | 304 | 2016 |
| Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 399 (10320), 143-151, 2022 | 240 | 2022 |
| Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet 400 (10349), 359-368, 2022 | 235 | 2022 |
| Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial E Abaleke, M Abbas, S Abbasi, A Abbott, A Abdelaziz, S Abdelbadiee, ... The Lancet 397 (10274), 605-612, 2021 | 212 | 2021 |
| Safety and immunogenicity of a two-dose heterologous Ad26. ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant … AJ Pollard, O Launay, JD Lelievre, C Lacabaratz, S Grande, N Goldstein, ... The Lancet Infectious Diseases 21 (4), 493-506, 2021 | 141 | 2021 |
| A monovalent chimpanzee adenovirus Ebola vaccine—preliminary report T Rampling, K Ewer, G Bowyer, D Wright, EB Imoukhuede, R Payne, ... New England Journal of Medicine, 2015 | 140 | 2015 |
| Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial E Abaleke, M Abbas, S Abbasi, A Abbott, A Abdelaziz, S Abdelbadiee, ... The Lancet 397 (10274), 605-612, 2021 | 122 | 2021 |
| MAIT cell clonal expansion and TCR repertoire shaping in human volunteers challenged with Salmonella Paratyphi A LJ Howson, G Napolitani, D Shepherd, H Ghadbane, P Kurupati, ... Nature communications 9 (1), 1-11, 2018 | 117 | 2018 |
| Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 397 (10289), 2049-2059, 2021 | 113 | 2021 |
| Typhoid and paratyphoid fever: a call to action MM Gibani, C Britto, AJ Pollard Current opinion in infectious diseases 31 (5), 440, 2018 | 108 | 2018 |
| Assessing a novel, lab-free, point-of-care test for SARS-CoV-2 (CovidNudge): a diagnostic accuracy study MM Gibani, C Toumazou, M Sohbati, R Sahoo, M Karvela, TK Hon, ... The Lancet Microbe 1 (7), e300-e307, 2020 | 107 | 2020 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 399 (10325), 665-676, 2022 | 77 | 2022 |
| A framework for controlled human infection model (CHIM) studies in Malawi: report of a Wellcome trust workshop on CHIM in low income countries held in Blantyre, Malawi SB Gordon, J Rylance, A Luck, K Jambo, DM Ferreira, L Manda-Taylor, ... Wellcome open research 2, 2017 | 72 | 2017 |
| Evaluation of the Clinical and Microbiological Response to Salmonella Paratyphi A Infection in the First Paratyphoid Human Challenge Model HC Dobinson, MM Gibani, C Jones, HB Thomaides-Brears, M Voysey, ... Clinical Infectious Diseases 64 (8), 1066-1073, 2017 | 71 | 2017 |
| Vi-specific serological correlates of protection for typhoid fever C Jin, J Hill, BM Gunn, WH Yu, LC Dahora, E Jones, M Johnson, ... Journal of Experimental Medicine 218 (2), 2021 | 63 | 2021 |
| Investigation of the role of typhoid toxin in acute typhoid fever in a human challenge model MM Gibani, E Jones, A Barton, C Jin, J Meek, S Camara, U Galal, E Heinz, ... Nature medicine 25 (7), 1082-1088, 2019 | 57 | 2019 |
| The Typhoid Vaccine Acceleration Consortium (TyVAC): vaccine effectiveness study designs: accelerating the introduction of typhoid conjugate vaccines and reducing the global … JE Meiring, M Gibani, B Basnyat, AD Bentsi-Enchill, J Clemens, ... Vaccine 35 (38), 5081-5088, 2017 | 47 | 2017 |
